Results 121 to 130 of about 17,496 (173)

Should New Anti-Malarial Drugs be Subsidized? [PDF]

open access: yes
We use analytical and numerical models to explain and quantify the welfare effects of subsidies for artemisinin combination treatments (ACTs), a valuable new class of antimalarial drugs.
Klein, Eili   +3 more
core  

Evaluation of artemisinins for the treatment of acute myeloid leukemia

open access: yesCancer Chemotherapy and Pharmacology, 2016
C. Drenberg   +9 more
semanticscholar   +1 more source

Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study

open access: yesLancet. Infectious Diseases (Print), 2016
K. Moore   +10 more
semanticscholar   +1 more source

Endoperoxide-based compounds: cross-resistance with artemisinins and selection of a Plasmodium falciparum lineage with a K13 non-synonymous polymorphism

open access: yesJournal of Antimicrobial Chemotherapy, 2018
L. Paloque   +10 more
semanticscholar   +1 more source

Inhibition of Human Cytomegalovirus Replication by Artemisinins: Effects Mediated through Cell Cycle Modulation

open access: yesAntimicrobial Agents and Chemotherapy, 2015
Sujayita Roy   +6 more
semanticscholar   +1 more source

A single amino acid residue can determine the sensitivity of SERCAs to artemisinins

open access: yesNature Structural &Molecular Biology, 2012
A. Uhlemann   +10 more
semanticscholar   +1 more source

Lack of Association of the S769N Mutation in Plasmodium falciparum SERCA (PfATP6) with Resistance to Artemisinins

open access: yesAntimicrobial Agents and Chemotherapy, 2012
Long Cui   +6 more
semanticscholar   +1 more source

Artemisinins: their growing importance in medicine [PDF]

open access: yesTrends in Pharmacological Sciences, 2008
Artemisinins are derived from extracts of sweet wormwood (Artemisia annua) and are well established for the treatment of malaria, including highly drug-resistant strains. Their efficacy also extends to phylogenetically unrelated parasitic infections such
Sanjeev Krishna   +2 more
exaly   +10 more sources

Home - About - Disclaimer - Privacy